12 May 2020 | News
The Aperio GT 450 DX System was rigorously tested by technicians and pathologists in Asia
US based Leica Biosystems, the global leader in pathology workflow solutions, announced that it has launched the Aperio GT 450 DX, its next generation digital pathology scanner, in the APAC region.
With continuous loading, no-touch operation, and 32 second scan time at 40x magnification, the Aperio GT 450 DX, registered as CE IVD and TGA, allows healthcare organizations to scale up digital pathology so they can meet ever-increasing demands without sacrificing quality.
The Aperio GT 450 DX System was rigorously tested by technicians and pathologists in Asia, including at Seoul National University Hospital (SNUH), a leading digital pathology hospital in South Korea, to determine the workflow impact.
"The Aperio GT 450 DX next generation imaging solution innovatively reduces the pre-scan process and scanner technician time, while maintaining sharp image quality and color for the pathologist. We expect that these workflow time savings will allow us to scale up our digital pathology operations instead of using the current conventional glass slide-based diagnosis," said Prof. Kyoungbun Lee, Department of Pathology, Seoul National University Hospital, who led the beta testing of the Aperio GT 450 DX.